The agency has provisionally determined that Selarsdi will be interchangeable with Stelara following the exclusivity ... injection at 45 mg/0.5 mL and 90 mg/mL, a single-dose vial for subcutaneous ...

Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn's disease. Clinical remission rates with ...

It encompasses all indications approved for the STELARA® reference product ... injection comes in two strengths: 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe.

It encompasses all indications approved for the STELARA ® reference product ... injection comes in two strengths: 45mg/0.5 mL or 90mg/1 mL solution in a single-dose, prefilled syringe.

The FDA has provisionally determined that SELARSDI will be interchangeable with the reference biologic Stelara®, following ... SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled ...

Otulfi ® is an ustekinumab biosimilar for the reference ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion.

representing over 95% savings compared to Stelara (90 mg)’s list price of $35,000 per fill. Employer groups that leverage the biosimilar stand to save a projected $14.5 million annually ...

Patients with moderate to severe psoriasis treated with ustekinumab and guselkumab showed a trend towards a lower risk for herpes zoster (HZ) and postherpetic neuralgia (PHN) than those receiving ...

STEQEYMA is available in both subcutaneous injection and intravenous infusion and is indicated for the treatment of plaque psoriasis (PsO) and psoriatic arthritis (PsA) in adult and pediatric patients ...

(Photo: Business Wire) The Fresenius ustekinumab biosimilar ... a 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for injection and a 130 mg/26 mL (5 mg/mL) single dose vial for IV ...